HK Innoen Adds Sixth Indication for K-Cab; "Most P-CAB Approvals in Korea"
"Key Driver for Blockbuster Drug Success"
On July 27, HK Innoen announced that it has added "prevention of peptic ulcers associated with nonsteroidal anti-inflammatory drugs (NSAIDs)" as the sixth indication for its new gastroesophageal reflux disease drug, K-Cab (active ingredient: tegoprazan).
K-Cab now has a total of six approved indications: treatment of erosive gastroesophageal reflux disease, treatment of non-erosive gastroesophageal reflux disease, treatment of gastric ulcers, combination antibiotic therapy for Helicobacter pylori eradication in patients with peptic ulcers or chronic atrophic gastritis, maintenance therapy after treatment of erosive gastroesophageal reflux disease, and prevention of peptic ulcer (gastric and duodenal ulcer) associated with NSAID use. This is the highest number of indications among P-CAB class therapies in Korea.
Due to the rapid increase in chronic pain patients driven by population aging, the demand for NSAIDs is on the rise. K-Cab is expected to provide a new option in the NSAID combination therapy market, which has previously been dominated by conventional PPI class drugs.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Dalwon Kwak, CEO of HK Innoen, stated, "Managing gastrointestinal adverse effects caused by long-term use of anti-inflammatory analgesics is an unmet global need. The robust clinical data accumulated through the addition of this new indication is expected to serve as a key driver for K-Cab to become a blockbuster drug not only in the domestic market but also in the global market."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.